Maze Therapeutics (NASDAQ:MAZE) CMO Sells 25,156 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 25,156 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $40.20, for a total transaction of $1,011,271.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Harold Bernstein also recently made the following trade(s):

• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.00, for a total transaction of $16,480.00.
• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.43, for a total value of $179,185.76.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00.

Maze Therapeutics Trading Up 3.5%

Shares of Maze Therapeutics stock traded up $1.37 during trading on Friday, reaching $40.32. The stock had a trading volume of 204,855 shares, compared to its average volume of 280,490. The company has a market capitalization of $1.94 billion and a price-to-earnings ratio of -1.93. The stock has a fifty day moving average price of $37.58 and a two-hundred day moving average price of $25.65. Maze Therapeutics, Inc. has a 52 week low of $6.71 and a 52 week high of $43.29.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.08.

Hedge Funds Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC bought a new stake in Maze Therapeutics in the second quarter valued at approximately $28,000. Ameritas Investment Partners Inc. increased its holdings in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after acquiring an additional 1,725 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Maze Therapeutics in the 3rd quarter valued at $52,000. Finally, Legal & General Group Plc lifted its holdings in Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after purchasing an additional 3,371 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MAZE. Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. BTIG Research lifted their target price on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Guggenheim reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Friday, December 19th. Finally, Raymond James Financial started coverage on Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $43.38.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.